The Effect of a Six-Month Exercise Program on Very Low-Density Lipoprotein Apolipoprotein B Secretion in Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 2, 2004, Pages 688-694

  Alam, Saima ^a   Stolinski, Michael ^a   Pentecost, Claire ^a   Boroujerdi, Massoud A ^a   Jones, Richard H ^a   Sonksen, Peter H ^a   Umpleby, A Margot ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CARBON 13; FATTY ACID; HEMOGLOBIN A1C; LEUCINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DYNAMIC EXERCISE; FEMALE; HEALTH PROGRAM; HUMAN; INFUSION; INSULIN SENSITIVITY; MALE; MUSCLE TRAINING; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SECRETION; RANDOMIZATION;

ADULT; AGED; APOLIPOPROTEINS B; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; FEMALE; HUMANS; INSULIN RESISTANCE; KINETICS; LIPIDS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; OBESITY; PHYSICAL FITNESS; QUALITY OF LIFE; TIME FACTORS;

EID: 1442303359     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031036     Document Type: Article

References (44)

1. Reaven GM 1988 Banting lecture: role of insulin resistance in human disease. Diabetes 37:1595-1607
2. Betteridge DJ 1999 Diabetic dyslipidaemia. Eur J Clin Invest 29(Suppl 2):12-16
3. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR 1998 Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316:823-828
4. Griffin BA, Freeman DJ, Tait GW, Thompson J, Caslake MJ, Packard CJ, Shepherd J 1994 Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small dense LDL to coronary heart disease. Atherosclerosis 106:241-253
5. Lehmann R, Vokac A, Niedermann K, Agosti K, Spinas GA 1995 Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. Diabetologia 38:1313-1319
6. Mourier A, Gautier JF, De Kerviler E, Bigard AX, Villette JM, Garnier JP, Duvallet A, Guezennec CY, Cathelineau G 1997 Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branched-chain amino acid supplements. Diabetes Care 20:385-391
7. Dixon JL, Ginsberg HN 1993 Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res 34:167-179
8. Sniderman A, Brown BG, Stewart BF, Cianflone K 1992 From familial combined hyperlipidaemia to hyperapoB: unravelling the overproduction of hepatic apolipoprotein B. Curr Opin Lipidol 3:137-142
9. Cummings MH, Watts GF, Umpleby AM, Hennessey TR, Kelly JM, Jackson NC, Sonksen PH 1995 Acute hyperinsulinaemia decreases the hepatic secretion of very low density lipoprotein B100 in type 2 diabetes mellitus: a stable isotope study. Diabetes 44:1059-1065
10. Watts GF, Cummings MH, Kelly JM, Umpleby AM, O'Brien SF, Sonksen PH 1996 Acute hyperinsulinaemia decreases hepatic secretion of very low density lipoprotein apolipoprotein B-100 in normolipidaemia non diabetic subjects. Endocrinol Metab 3:253-263
11. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova R, Slavin BM, Thompson GR, Sonksen PH 1995 Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in NIDDM. Diabetologia 38:959-967
12. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B 2000 Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 30:685-694
13. 1998 ACSM resource manual guidelines. 3rd ed. Baltimore: Williams and Wilkins
14. Miller WR, Rollnick S 1991 Motivational interviewing: preparing to change addictive behaviour. New York: Guilford Press
15. Rollnick S, Mason P, Butler C 2000 Health behaviour change: a guide for practitioners. Edinburgh: Harcourt Brace, Churchill, Livingstone
16. Matthews DE, Schwartz HP, Yand RD, Motil KJ, Bier D 1982 Relationship of plasma leucine and α-ketoisocaproate during L[1-13C] leucine infusion in man: a method for measuring human intracellular leucine tracer enrichment. Metabolism 31:1105-1112
17. Bradley C 1994 The well-being questionnaire. In: Bradley C, Ed. Handbook of psychology and diabetes. Chur, Switzerland: Harwood Academic Publishers; 84-109
18. Kane JP, Sata T, Hamilton RL 1975 Apoprotein composition of very low density lipoproteins of human serum. J Clin Invest 56:1622-1634
19. Cummings MH, Watts GF, Lumb PJ, Slavin BM 1994 Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma. J Clin Pathol 47:176-178
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
21. Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR 1998 Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 22:414-423
22. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y 1995 Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 89:748-756
23. Kissebah AH, Alfarsi S, Evans DJ, Adams PW 1982 Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 31:217-225
24. Malmstrom R, Packard CJ, Watson TDG, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen M-R 1997 Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454-1464
25. Sparks JD, Sparks CE, Miller LL 1989 Insulin effects on apolipoprotein B production by normal, diabetic, and treated-diabetic rat liver and cultured rat hepatocytes. Biochem J 261:83-88
26. Salhanick AI, Schwartz SI, Amatruda JM 1991 Insulin inhibits apolipoprotein B secretion in isolated human hepatocytes. Metabolism 40:275-279
27. Lin MC, Gordon D, Wetterau JR 1995 Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 36:1073-1081
28. Carpentier A, Taghibiglou C, Leung N, Szeto L, Van Iderstine SC, Uffelman KD, Buckingham R, Adeli K, Lewis GF 2002 Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 277:28795-28802
29. Sniderman AD, Cianflone K 1993 Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 13:629-636
30. Coppack SW, Jensen MD, Miles JM 1994 In vivo regulation of lipolysis in humans. J Lipid Res 35:177-193
31. Carpentier A, Patterson BW, Leung N, Lewis GF 2002 Sensitivity to acute insulin mediated suppression of plasma fatty acids is not a determinant of fasting VLDL triglyceride secretion in healthy humans. Diabetes 51:1867-1875
32. Lewis GF, Zinman B, Uffelman KD, Szeto L, Weller B, Steiner G 1995 Interaction between free fatty acids and insulin in acute control of very-low density lipoprotein production in humans. J Clin Invest 95:158-166
33. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR 1998 Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 47:779-787
34. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C 1990 Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497-511
35. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barret PH 1999 Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 84:2854-2861
36. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H 2000 Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758
37. Homko CJ, Cheung P, Boden G 2003 Effects of free fatty acids on glucose uptake and utilization in healthy women. Diabetes 52:487-491
38. De Glisezinski I, Crampes F, Harant I, Berlan M, Hejnova J, Langin D, Riviere D, Stich V 1998 Endurance training changes in lipolytic responsiveness of obese adipose tissue. Am J Physiol 275:E951-E956
39. Eckel RH 1989 Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med. 320:1060-1068
40. Lehmann R, Engler H, Honegger R, Riesen W, Spinas GA 2001 Alterations of lipolytic enzymes and high-density lipoprotein subfractions induced by physical activity in type 2 diabetes. Eur J Clin Invest 31:37-44
41. Ligtenberg PC, Godaert GL, Hillenaar EF, Hoekstra JB 1998 Influence of a physical training program on psychological well-being in elderly type 2 diabetes patients. Diabetes Care 21:2196-2197
42. Wilmore JH, Green JS, Stanforth PR, Gagnon J, Rankinen T, Leon AS, Rao DC, Skinner JS, Bouchard C 2001 Relationship of changes in maximal and submaximal aerobic fitness to changes in cardiovascular disease and non-insulin-dependent diabetes mellitus risk factors with endurance training: the HERITAGE Family Study. Metabolism 50:1255-1263
43. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR 2003 DAIS Group: relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733-1737
44. Mack WJ, Krauss RM, Hodis HN 1996 Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 16:697-704